Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase
Article first published online: 22 SEP 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 68, Issue 6, pages 920–927, December 2009
How to Cite
Greenblatt, D. J., Peters, D. E., Oleson, L. E., Harmatz, J. S., MacNab, M. W., Berkowitz, N., Zinny, M. A. and Court, M. H. (2009), Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. British Journal of Clinical Pharmacology, 68: 920–927. doi: 10.1111/j.1365-2125.2009.03545.x
- Issue published online: 27 NOV 2009
- Article first published online: 22 SEP 2009
- Received 14 April 2009 Accepted17 August 2009
- 1Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89–96., , , , .
- 2Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000; 292: 618–28., , , , , .
- 3Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783–91., , , , , , .
- 4Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298–304., , , .
- 5The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815–32., , , , , , , , , , , , , , , , , , , , , .
- 6Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus. Br J Clin Pharmacol 2001; 52: 107–17., , .
- 7New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48: 662–70., , , , , , , , , , , , , , , , , , , , , , , , , , , , , .
- 8CYP3A4 substrate selection and substitution in the prediction of potential drug–drug interactions. J Pharmacol Exp Ther 2005; 314: 180–90., , , .
- 9The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 2006; 316: 336–48., , , , , .
- 10The conduct of in vitro and in vivo drug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443–69., , , , , , , , , , , , , , , , , , , , , .
- 11Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216., , .
- 12An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 153–8., , , .
- 13Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27–35., , , , , .
- 14Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461–71., , , .
- 15Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007; 47: 286–94., , , , , , .
- 16The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74: 275–87., , , , , , .
- 17The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133–43., , , , , .
- 18Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718–28., , , , , .
- 19Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76: 250–69., , , .
- 20Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–8., , , , .
- 21Intestinal first pass metabolism of midazolam in liver cirrhosis—effect of grapefruit juice. Br J Clin Pharmacol 2002; 54: 120–4., , , , .
- 22Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831–9., , , , , , , .
- 23Time-course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003; 74: 121–9., , , , , , , , .
- 24Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006; 34: 1208–19., , , , , .
- 25Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004; 60: 237–46., , , , , , , , , , .
- 26Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006; 79: 350–61., , , .
- 27Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999; 39: 1212–20., , , , , , , , , .
- 28Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24: 129–36., , , , , , , , .
- 29Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84: 75–82., , , , , , , , , , , , , , , , .
- 30Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008; 49: 358–68., , , , , .
- 31Dose–response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85: 64–70., , , .
- 32Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 2008; 84: 506–12., , , , .
- 33Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52–60., , , , , , , , , .
- 34Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br J Clin Pharmacol 2006; 62: 200–9., , , , , , , .
- 35Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865–73., , , , , , , .
- 36Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev 2004; 104: 6255–85., , .
- 37Glutathione peroxidase mimics prevent TNFalpha- and neutrophil-induced endothelial alterations. Free Radic Biol Med 1998; 25: 270–81., , , , .
- 38ICAM-1 and VCAM-1 expression induced by TNF-alpha are inhibited by a glutathione peroxidase mimic. Free Radic Biol Med 1998; 24: 979–87., , , , .
- 39Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol 2000; 279: C1880–8., , , , .
- 40Neuroprotective effects of a new glutathione peroxidase mimetic on neurons of the chick embryo's retina. J Neurosci Res 2000; 59: 497–503., .
- 41Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol 2007; 49: 82–7., , , , , , , , , , , , .
- 42Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. J Pharmacol Toxicol Methods 1999; 40: 235–9., , , .
- 43Preparation of scientific reports on pharmacokinetic drug interaction studies. J Clin Psychopharmacol 2008; 28: 369–73..
- 44Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008; 48: 1350–5., .
- 45Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106–11., , , , , , , , .
- 46Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98: 79–85., , , , , .
- 47Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190–4., , .
- 48Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259–61., , , .
- 49ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218–24., , , , , , , , , , , , , , , , , , , , , , , , , , .
- 50Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99–107., , , , .
- 51Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29–33., , , , , , , , .
- 52Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654–60., , , , , , , , , , , , , , .
- 53Short term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43: 414–22., , , , , , , , , , , .
- 54Alprazolam–ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000; 67: 335–41., , , , , , , , .
- 55Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharm Ther 2006; 79: 243–54., , , , , , , .
- 56Guidance for Industry. Drug Interaction Studies. G:/6695dft.doc, 9/8/06. Available at http://www.FDA.gov/CEDR/guidance/index.htm (last accessed 9 October 2009).